Evaluation of indapamide 1.25 mg once daily in elderly patients with mild to moderate hypertension
The objective of this study was to evaluate the safety and efficacy of indapamide 1.25 mg once daily as monotherapy in elderly patients (65 years and older) with mild to moderate essential hypertension. Two hundred and seventy-nine (279) elderly patients were enrolled in a washout period, during whi...
Gespeichert in:
Veröffentlicht in: | Journal of human hypertension 1997-04, Vol.11 (4), p.239-244 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 244 |
---|---|
container_issue | 4 |
container_start_page | 239 |
container_title | Journal of human hypertension |
container_volume | 11 |
creator | FIDDES, R BLUMENTHAL, J RATNER, P. H ROSENBLATT, S TOTH, P. D VERGIS, J CODISPOTI, J DAWSON, J. E DYCKMAN, E ST JOHN HAMMONDS, P. G HARRIS, S LASSETER, K. C LEVINE, B. S MONTORO, R NIEDERMAN, A. L |
description | The objective of this study was to evaluate the safety and efficacy of indapamide 1.25 mg once daily as monotherapy in elderly patients (65 years and older) with mild to moderate essential hypertension. Two hundred and seventy-nine (279) elderly patients were enrolled in a washout period, during which patients received single-blind placebo for 4 weeks. Patients demonstrating supine diastolic pressures between 95 mm Hg and 114 mm Hg at the end of the 4-week placebo washout period were entered into the 8-week double-blind treatment period. Two hundred and four (204) patients qualified for the study and were randomized to the double-blind treatment; 103 patients received indapamide 1.25 mg and 101 patients received placebo for 8 weeks. Overall, 177 patients (92 indapamide and 85 placebo) completed the study. The primary efficacy criterion was the mean change in supine diastolic blood pressure (DBP) from double-blind baseline to the end of 8 weeks of therapy. By week 8 of the double-blind treatment period, indapamide 1.25 mg produced a statistically significant (P = 0.0037) decrease in supine DBP of 8.2 mm Hg compared to a decrease of 5.3 mm Hg produced in the placebo group. Additionally, indapamide 1.25 mg was statistically (P = 0.0028) more effective than placebo in reducing supine systolic BP (SBP) (-10.1 vs -4.2 mm Hg). The incidence of drug-related adverse events during the double-blind treatment period was similar between the two treatment groups. A low dose of indapamide, 1.25 mg, given once daily for 8 weeks was effective as monotherapy with respect to BP reduction in an elderly population with mild to moderate hypertension. Indapamide 1.25 mg was safe and generally well tolerated in this elderly patient population. |
doi_str_mv | 10.1038/sj.jhh.1000419 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2640665323</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2640665323</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-844da82afab0916a03ae79917879c4d2491fc5171a788544e9eab4df667852373</originalsourceid><addsrcrecordid>eNo9kEtLxDAUhYMo4zi6dScEdNsxSfNciowPGHCj63KnSW1LXyatMv_eDFNmdQ985557OQjdUrKmJNWPoV7XZRk1IZyaM7SkXMlECKbO0ZIYQRLDOLlEVyHUhBygXqCFoVoQZpZot_mFZoKx6jvcF7jqLAzQVtZhumYCt9-473KHLVTNPlLsGut8lENccd0Y8F81lritGovHHrd9pDA6XO4H50fXhZh7jS4KaIK7mecKfb1sPp_fku3H6_vz0zbJU67GRHNuQTMoYEcMlUBScMoYqrQyObeMG1rkgioKSmvBuTMOdtwWUiotWKrSFbo_5g6-_5lcGLO6n3wXT2ZMciKlSFkaXeujK_d9CN4V2eCrFvw-oyQ7NJqFOouNZnOjceFujp12rbMn-1xh5A8zh5BDU3jo8iqcbEzG_5lM_wGdHH4O</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2640665323</pqid></control><display><type>article</type><title>Evaluation of indapamide 1.25 mg once daily in elderly patients with mild to moderate hypertension</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>FIDDES, R ; BLUMENTHAL, J ; RATNER, P. H ; ROSENBLATT, S ; TOTH, P. D ; VERGIS, J ; CODISPOTI, J ; DAWSON, J. E ; DYCKMAN, E ; ST JOHN HAMMONDS, P. G ; HARRIS, S ; LASSETER, K. C ; LEVINE, B. S ; MONTORO, R ; NIEDERMAN, A. L</creator><creatorcontrib>FIDDES, R ; BLUMENTHAL, J ; RATNER, P. H ; ROSENBLATT, S ; TOTH, P. D ; VERGIS, J ; CODISPOTI, J ; DAWSON, J. E ; DYCKMAN, E ; ST JOHN HAMMONDS, P. G ; HARRIS, S ; LASSETER, K. C ; LEVINE, B. S ; MONTORO, R ; NIEDERMAN, A. L</creatorcontrib><description>The objective of this study was to evaluate the safety and efficacy of indapamide 1.25 mg once daily as monotherapy in elderly patients (65 years and older) with mild to moderate essential hypertension. Two hundred and seventy-nine (279) elderly patients were enrolled in a washout period, during which patients received single-blind placebo for 4 weeks. Patients demonstrating supine diastolic pressures between 95 mm Hg and 114 mm Hg at the end of the 4-week placebo washout period were entered into the 8-week double-blind treatment period. Two hundred and four (204) patients qualified for the study and were randomized to the double-blind treatment; 103 patients received indapamide 1.25 mg and 101 patients received placebo for 8 weeks. Overall, 177 patients (92 indapamide and 85 placebo) completed the study. The primary efficacy criterion was the mean change in supine diastolic blood pressure (DBP) from double-blind baseline to the end of 8 weeks of therapy. By week 8 of the double-blind treatment period, indapamide 1.25 mg produced a statistically significant (P = 0.0037) decrease in supine DBP of 8.2 mm Hg compared to a decrease of 5.3 mm Hg produced in the placebo group. Additionally, indapamide 1.25 mg was statistically (P = 0.0028) more effective than placebo in reducing supine systolic BP (SBP) (-10.1 vs -4.2 mm Hg). The incidence of drug-related adverse events during the double-blind treatment period was similar between the two treatment groups. A low dose of indapamide, 1.25 mg, given once daily for 8 weeks was effective as monotherapy with respect to BP reduction in an elderly population with mild to moderate hypertension. Indapamide 1.25 mg was safe and generally well tolerated in this elderly patient population.</description><identifier>ISSN: 0950-9240</identifier><identifier>EISSN: 1476-5527</identifier><identifier>DOI: 10.1038/sj.jhh.1000419</identifier><identifier>PMID: 9185029</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing</publisher><subject>Aged ; Aged, 80 and over ; Antihypertensive agents ; Biological and medical sciences ; Blood pressure ; Blood Pressure Determination ; Cardiovascular system ; Diuretics - administration & dosage ; Diuretics - adverse effects ; Diuretics - therapeutic use ; Double-Blind Method ; Drug Administration Schedule ; Female ; Humans ; Hypertension ; Hypertension - drug therapy ; Hypertension - physiopathology ; Indapamide ; Indapamide - administration & dosage ; Indapamide - adverse effects ; Indapamide - therapeutic use ; Male ; Medical sciences ; Patients ; Pharmacology. Drug treatments ; Placebos ; Statistical analysis ; Treatment Outcome</subject><ispartof>Journal of human hypertension, 1997-04, Vol.11 (4), p.239-244</ispartof><rights>1997 INIST-CNRS</rights><rights>Macmillan Publishers Limited 1997.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-844da82afab0916a03ae79917879c4d2491fc5171a788544e9eab4df667852373</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2687926$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9185029$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FIDDES, R</creatorcontrib><creatorcontrib>BLUMENTHAL, J</creatorcontrib><creatorcontrib>RATNER, P. H</creatorcontrib><creatorcontrib>ROSENBLATT, S</creatorcontrib><creatorcontrib>TOTH, P. D</creatorcontrib><creatorcontrib>VERGIS, J</creatorcontrib><creatorcontrib>CODISPOTI, J</creatorcontrib><creatorcontrib>DAWSON, J. E</creatorcontrib><creatorcontrib>DYCKMAN, E</creatorcontrib><creatorcontrib>ST JOHN HAMMONDS, P. G</creatorcontrib><creatorcontrib>HARRIS, S</creatorcontrib><creatorcontrib>LASSETER, K. C</creatorcontrib><creatorcontrib>LEVINE, B. S</creatorcontrib><creatorcontrib>MONTORO, R</creatorcontrib><creatorcontrib>NIEDERMAN, A. L</creatorcontrib><title>Evaluation of indapamide 1.25 mg once daily in elderly patients with mild to moderate hypertension</title><title>Journal of human hypertension</title><addtitle>J Hum Hypertens</addtitle><description>The objective of this study was to evaluate the safety and efficacy of indapamide 1.25 mg once daily as monotherapy in elderly patients (65 years and older) with mild to moderate essential hypertension. Two hundred and seventy-nine (279) elderly patients were enrolled in a washout period, during which patients received single-blind placebo for 4 weeks. Patients demonstrating supine diastolic pressures between 95 mm Hg and 114 mm Hg at the end of the 4-week placebo washout period were entered into the 8-week double-blind treatment period. Two hundred and four (204) patients qualified for the study and were randomized to the double-blind treatment; 103 patients received indapamide 1.25 mg and 101 patients received placebo for 8 weeks. Overall, 177 patients (92 indapamide and 85 placebo) completed the study. The primary efficacy criterion was the mean change in supine diastolic blood pressure (DBP) from double-blind baseline to the end of 8 weeks of therapy. By week 8 of the double-blind treatment period, indapamide 1.25 mg produced a statistically significant (P = 0.0037) decrease in supine DBP of 8.2 mm Hg compared to a decrease of 5.3 mm Hg produced in the placebo group. Additionally, indapamide 1.25 mg was statistically (P = 0.0028) more effective than placebo in reducing supine systolic BP (SBP) (-10.1 vs -4.2 mm Hg). The incidence of drug-related adverse events during the double-blind treatment period was similar between the two treatment groups. A low dose of indapamide, 1.25 mg, given once daily for 8 weeks was effective as monotherapy with respect to BP reduction in an elderly population with mild to moderate hypertension. Indapamide 1.25 mg was safe and generally well tolerated in this elderly patient population.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antihypertensive agents</subject><subject>Biological and medical sciences</subject><subject>Blood pressure</subject><subject>Blood Pressure Determination</subject><subject>Cardiovascular system</subject><subject>Diuretics - administration & dosage</subject><subject>Diuretics - adverse effects</subject><subject>Diuretics - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - physiopathology</subject><subject>Indapamide</subject><subject>Indapamide - administration & dosage</subject><subject>Indapamide - adverse effects</subject><subject>Indapamide - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Placebos</subject><subject>Statistical analysis</subject><subject>Treatment Outcome</subject><issn>0950-9240</issn><issn>1476-5527</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtLxDAUhYMo4zi6dScEdNsxSfNciowPGHCj63KnSW1LXyatMv_eDFNmdQ985557OQjdUrKmJNWPoV7XZRk1IZyaM7SkXMlECKbO0ZIYQRLDOLlEVyHUhBygXqCFoVoQZpZot_mFZoKx6jvcF7jqLAzQVtZhumYCt9-473KHLVTNPlLsGut8lENccd0Y8F81lritGovHHrd9pDA6XO4H50fXhZh7jS4KaIK7mecKfb1sPp_fku3H6_vz0zbJU67GRHNuQTMoYEcMlUBScMoYqrQyObeMG1rkgioKSmvBuTMOdtwWUiotWKrSFbo_5g6-_5lcGLO6n3wXT2ZMciKlSFkaXeujK_d9CN4V2eCrFvw-oyQ7NJqFOouNZnOjceFujp12rbMn-1xh5A8zh5BDU3jo8iqcbEzG_5lM_wGdHH4O</recordid><startdate>19970401</startdate><enddate>19970401</enddate><creator>FIDDES, R</creator><creator>BLUMENTHAL, J</creator><creator>RATNER, P. H</creator><creator>ROSENBLATT, S</creator><creator>TOTH, P. D</creator><creator>VERGIS, J</creator><creator>CODISPOTI, J</creator><creator>DAWSON, J. E</creator><creator>DYCKMAN, E</creator><creator>ST JOHN HAMMONDS, P. G</creator><creator>HARRIS, S</creator><creator>LASSETER, K. C</creator><creator>LEVINE, B. S</creator><creator>MONTORO, R</creator><creator>NIEDERMAN, A. L</creator><general>Nature Publishing</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>19970401</creationdate><title>Evaluation of indapamide 1.25 mg once daily in elderly patients with mild to moderate hypertension</title><author>FIDDES, R ; BLUMENTHAL, J ; RATNER, P. H ; ROSENBLATT, S ; TOTH, P. D ; VERGIS, J ; CODISPOTI, J ; DAWSON, J. E ; DYCKMAN, E ; ST JOHN HAMMONDS, P. G ; HARRIS, S ; LASSETER, K. C ; LEVINE, B. S ; MONTORO, R ; NIEDERMAN, A. L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-844da82afab0916a03ae79917879c4d2491fc5171a788544e9eab4df667852373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antihypertensive agents</topic><topic>Biological and medical sciences</topic><topic>Blood pressure</topic><topic>Blood Pressure Determination</topic><topic>Cardiovascular system</topic><topic>Diuretics - administration & dosage</topic><topic>Diuretics - adverse effects</topic><topic>Diuretics - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - physiopathology</topic><topic>Indapamide</topic><topic>Indapamide - administration & dosage</topic><topic>Indapamide - adverse effects</topic><topic>Indapamide - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Placebos</topic><topic>Statistical analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FIDDES, R</creatorcontrib><creatorcontrib>BLUMENTHAL, J</creatorcontrib><creatorcontrib>RATNER, P. H</creatorcontrib><creatorcontrib>ROSENBLATT, S</creatorcontrib><creatorcontrib>TOTH, P. D</creatorcontrib><creatorcontrib>VERGIS, J</creatorcontrib><creatorcontrib>CODISPOTI, J</creatorcontrib><creatorcontrib>DAWSON, J. E</creatorcontrib><creatorcontrib>DYCKMAN, E</creatorcontrib><creatorcontrib>ST JOHN HAMMONDS, P. G</creatorcontrib><creatorcontrib>HARRIS, S</creatorcontrib><creatorcontrib>LASSETER, K. C</creatorcontrib><creatorcontrib>LEVINE, B. S</creatorcontrib><creatorcontrib>MONTORO, R</creatorcontrib><creatorcontrib>NIEDERMAN, A. L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Journal of human hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FIDDES, R</au><au>BLUMENTHAL, J</au><au>RATNER, P. H</au><au>ROSENBLATT, S</au><au>TOTH, P. D</au><au>VERGIS, J</au><au>CODISPOTI, J</au><au>DAWSON, J. E</au><au>DYCKMAN, E</au><au>ST JOHN HAMMONDS, P. G</au><au>HARRIS, S</au><au>LASSETER, K. C</au><au>LEVINE, B. S</au><au>MONTORO, R</au><au>NIEDERMAN, A. L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of indapamide 1.25 mg once daily in elderly patients with mild to moderate hypertension</atitle><jtitle>Journal of human hypertension</jtitle><addtitle>J Hum Hypertens</addtitle><date>1997-04-01</date><risdate>1997</risdate><volume>11</volume><issue>4</issue><spage>239</spage><epage>244</epage><pages>239-244</pages><issn>0950-9240</issn><eissn>1476-5527</eissn><abstract>The objective of this study was to evaluate the safety and efficacy of indapamide 1.25 mg once daily as monotherapy in elderly patients (65 years and older) with mild to moderate essential hypertension. Two hundred and seventy-nine (279) elderly patients were enrolled in a washout period, during which patients received single-blind placebo for 4 weeks. Patients demonstrating supine diastolic pressures between 95 mm Hg and 114 mm Hg at the end of the 4-week placebo washout period were entered into the 8-week double-blind treatment period. Two hundred and four (204) patients qualified for the study and were randomized to the double-blind treatment; 103 patients received indapamide 1.25 mg and 101 patients received placebo for 8 weeks. Overall, 177 patients (92 indapamide and 85 placebo) completed the study. The primary efficacy criterion was the mean change in supine diastolic blood pressure (DBP) from double-blind baseline to the end of 8 weeks of therapy. By week 8 of the double-blind treatment period, indapamide 1.25 mg produced a statistically significant (P = 0.0037) decrease in supine DBP of 8.2 mm Hg compared to a decrease of 5.3 mm Hg produced in the placebo group. Additionally, indapamide 1.25 mg was statistically (P = 0.0028) more effective than placebo in reducing supine systolic BP (SBP) (-10.1 vs -4.2 mm Hg). The incidence of drug-related adverse events during the double-blind treatment period was similar between the two treatment groups. A low dose of indapamide, 1.25 mg, given once daily for 8 weeks was effective as monotherapy with respect to BP reduction in an elderly population with mild to moderate hypertension. Indapamide 1.25 mg was safe and generally well tolerated in this elderly patient population.</abstract><cop>Basingstoke</cop><pub>Nature Publishing</pub><pmid>9185029</pmid><doi>10.1038/sj.jhh.1000419</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0950-9240 |
ispartof | Journal of human hypertension, 1997-04, Vol.11 (4), p.239-244 |
issn | 0950-9240 1476-5527 |
language | eng |
recordid | cdi_proquest_journals_2640665323 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Aged Aged, 80 and over Antihypertensive agents Biological and medical sciences Blood pressure Blood Pressure Determination Cardiovascular system Diuretics - administration & dosage Diuretics - adverse effects Diuretics - therapeutic use Double-Blind Method Drug Administration Schedule Female Humans Hypertension Hypertension - drug therapy Hypertension - physiopathology Indapamide Indapamide - administration & dosage Indapamide - adverse effects Indapamide - therapeutic use Male Medical sciences Patients Pharmacology. Drug treatments Placebos Statistical analysis Treatment Outcome |
title | Evaluation of indapamide 1.25 mg once daily in elderly patients with mild to moderate hypertension |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A29%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20indapamide%201.25%20mg%20once%20daily%20in%20elderly%20patients%20with%20mild%20to%20moderate%20hypertension&rft.jtitle=Journal%20of%20human%20hypertension&rft.au=FIDDES,%20R&rft.date=1997-04-01&rft.volume=11&rft.issue=4&rft.spage=239&rft.epage=244&rft.pages=239-244&rft.issn=0950-9240&rft.eissn=1476-5527&rft_id=info:doi/10.1038/sj.jhh.1000419&rft_dat=%3Cproquest_cross%3E2640665323%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2640665323&rft_id=info:pmid/9185029&rfr_iscdi=true |